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OBJECTIVES: To examine the unit cost of inpatient service department of special
ward at Banphaeo Hospital that reformed to be Public Organization( the new
model) in Thailand. METHODS: Cost analysis from provider’s perspective. Cost
center was divided by function and the support units in hospitals into three cate-
gories: (1)Patient service PS (2) Revenue producing cost center RPCC ; and (3) non
revenue producing cost center NRPCC. Total direct costs were composed of labour
costs, material costs and capital costs. Indirect costs were allocated by using direct
distribution method. RESULTS: The total cost of private ward 4/2 was
17,278,303.45 . The total cost in private ward 4/2 consisted of labour cost was
3,739,743.60 , material cost was 1,242,991.36 Capital cost was 2,733,735.87 . The
ratio of lobour cost: material cost: capital cost was 48.46: 16.11: 35.43 and ratio of
indirect cost was 55.34. The unit cost of inpatient department private ward 4/2 was
16,239 per case ; routine service cost was 9,226 . 10 and medical care cost was
7,012.90 CONCLUSIONS: The results were useful in decision making for resource
allocation. It can be used to facilitate comparison of different studies in various
type of organization of hospital administration.
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OBJECTIVES: o review the approach used in the CEA literature to estimate the cost
of EPI activities, other than vaccine purchase, for rotavirus and pneumococcal
vaccines. METHODS: A systematic review in PubMed database of rotavirus and
pneumococcal vaccines CEAs was done. Selected articles were read and informa-
tion on how EPI costs were calculated was extracted. EPI costing approaches were
classified according to the method or assumption used for estimation. RESULTS:
Thirty studies that evaluated Cost effectiveness of rota (n19) or pneumococcal
(n11) vaccines were identified. In general there are very few details on how EPI
costs different to vaccine purchasing were estimated. Only 2 studies (Canada) on
pneumococcal vaccine used a primary cost evaluations (micro costing) while 8
studies did not consider any additional EPI cost beyond vaccine purchasing. Eigh-
teen studies considered an overall administrative costs ranging betweenUS$0.5-10
per dose, but most of them did not provide any clue on the basis of that assump-
tion. Only 2 studies considered clearly costs related to personnel time or activities
which is a critical component of EPI costs.CONCLUSIONS:Most pneumococcal and
rotavirus cost-effectiveness analysis reviewednot considered additional EPI cost or
use assumptions based in no or few evidence. Ignoring additional EPI costs to
vaccine purchasing in CEA analysis of new vaccines may lead to significant errors
in the estimations of ICER since several aspects like cold chain, promotion activi-
ties or personnel can be substantially affected for the introduction of new vaccines.
This may lead to mistakes in the decision making process.
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OBJECTIVES: There is growing interest in using patient-reported outcome (PRO)
measures, which can complement clinical measures, to improve the quality of
health care. The amount of PRO data being captured by health care databases,
however, is unknown. To help identify data sources that capture PRO measures
and the types of PRO data they collect, a systematic review was conducted in
B.R.I.D.G.E. TO DATA® (www.bridgetodata.org), an online resource of population
healthcare database profiles worldwide. METHODS: PRO data were categorized
into 9 dimensions of health status (Fitzpatrick et al., 1998): physical function, symp-
toms, self-judgments of health, psychological well-being, social well-being, cogni-
tive function, role activities, personal constructs, and satisfaction with care. To
identify data sources collecting PRO data, 154 database profiles in www.bridgeto-
data.org were individually reviewed. The PRO category and specific data subcate-
gory (e.g., symptoms-appetite) were also extracted. RESULTS: A review of 154 da-
tabase profiles resulted in the identification of 34 databases that collect data on:
physical function (22), symptoms (19), psychological well-being (15), social well-
being (11), cognitive function (9), role activities (6), personal constructs (4), satisfac-
tion with care (2), and self-judgments of health (1). Three additional databases
(from UK, Netherlands, and Canada) collect PRO-related data upon request. The
majority of databases found to report PRO data are longitudinal and/or cross-sec-
tional, particularly survey data in populations of 200,000. US, Canadian, and UK
databases commonly report PRO data. Database characteristics vary among PRO
categories, including cognitive function, where population type primarily com-
prises of people from specialty institutions. CONCLUSIONS: Within 154 database
profiles that were reviewed, symptoms and physical function are the most fre-
quently collected PRO data types, while patient satisfaction with care and self-
judgments of health are least likely to be found. Reporting PRO data has become
increasingly important for health care; however, this study shows that less than
25% of databases collect any PRO data.
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OBJECTIVES: Secondary data sources can provide a wide variety of useful data for
research studies, but their utility depends on their validity. It is unclear whether
the extent to which secondary sources are used differs between research-oriented
and practice-oriented journals. The objectives of this study were to describe the
proportion of original research articles using secondary data, the types of second-
ary data being used, andwhether validationwasmentionedwhile comparing these
findings between two types of journals. METHODS: All original research articles
published in 2010 from selected practice-oriented journals (New England Journal of
Medicine, Archives of Internal Medicine, Pharmacotherapy, Annals of Pharmacotherapy)
and research-oriented journals (Value in Health, Medical Care, Health Services Re-
search) were reviewed. The complete text of each article was examined to deter-
mine whether secondary data were used, the type of secondary data used, and
whether validation of the data wasmentioned. The proportion of original research
articles using secondary data and the mention of validation was compared be-
tween the two types of journals using Fisher’s exact test. RESULTS: There were 192
and 425 original research articles for the research- and practice-oriented articles,
respectively. Overall, 44.1% of research articles used secondary data. Articles in
research-oriented journals were more likely than practice-oriented journals to use
secondary data (69.8% vs. 32.5%, respectively; p 0.001) and to mention validation
(17.2% versus 5.8%, respectively; p  0.003). Administrative data were the most
common secondary data source in the research journals compared to medical
records in the practice journals. CONCLUSIONS: The use of secondary sources was
more common in research-oriented journals than in practice-oriented journals. A
variety of secondary sources were used in published articles. Validation was men-
tionedmore frequently in research journals than in practice journals, but the over-
all percentage was relatively low for both types of journals.
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OBJECTIVES: Health economic researchers use electronic databases to review cur-
rent and ancestral literature across therapy areas. In the United States and Canada,
researchers tend to use MEDLINE, and in other parts of the world EMBASE is the
literature database of choice. EMBASE is fee-based and MEDLINE is available gratis
through the National Library of Medicine. Using the search engine OVID, both
databases can be searched simultaneously, with a paid subscription. MEDLINE
indexes 5600 journals and EMBASE indexes 7600 journals; all MEDLINE records are
included in EMBASE. EMBASE also includes conference abstracts which MEDLINE
does not. Additionally, EMBASE assigns more index terms to references thanMED-
LINE which can result in less focused searches. The researchers were interested in
comparing and contrasting search results in both databases, particularly in the
area of health economics. METHODS: Researchers selected three broad search
terms: cost of illness (COI), burden of illness (BOI) and cost benefit analysis (CBA)
that would be recognized in both databases. Each search was run with chronic
pulmonary obstructive disease as the treatment focus, 2010-2011, English only.
RESULTS: The results were unexpectedly mixed. In the area of CBA, MEDLINE
generated a higher number of references, 30 versus 17 in EMBASE with 11 dupli-
cated records. COI and BOI searches resulted in a larger number of citations for
EMBASE, 11 and 149, versus 7 and 105 for MEDLINE with 6 and 101 duplicates,
respectively. Conference abstracts accounted for the higher number of hits in EM-
BASE over MEDLINE. CONCLUSIONS: Health economic researchers rely on the
most up-to-date information to identify cost and treatment trends and the inclu-
sion of conference abstracts in EMBASE support conducting these searches using
both databases, particularly for systematic literature reviewswhere use of EMBASE
could be a requirement. Further examination into the nuances of search terms and
indexing in both databases is warranted.
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OBJECTIVES: To describe and compare two methods of ustekinumab drug utiliza-
tion evaluation in pharmacy claims. METHODS: Method I (fill pattern) was a drug
utilization assessment based on unadjusted raw claims. The National Drug Code,
quantity, days supplied, and cost of prescription were used. Method II (dosing
pattern) enhanced Method I by combining information on the current claim with
information on time to next prescription. This enhancement accounted for multi-
ple vials/syringes dispensed in a single claim to cover two doses. Only patientswith
2 ustekinumab prescriptions and meeting dosing algorithm requirements were
eligible forMethod II. A comparison of dosing results fromWolters Kluwer Source®
Lx, across the first three ustekinumab prescriptions, was used for illustration. Cal-
culated ustekinumab cost per injection was based on Wholesale Acquisition Cost
(effective 7/5/2011) of $5,485.22 per 45mg and distribution of 45 mg and 90 mg
dosing events. RESULTS: Data from 1039 patients were evaluated in Method I. A
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